Ipsen, Skyhawk ink deal worth up to $1.8B; Hepion to wind down NASH trial

Plus, news about Aslan, Take­da, Astel­las, Sum­it­o­mo Mit­sui, Kynos Ther­a­peu­tics, Oculis and Vaxxin­i­ty:

Ipsen, Sky­hawk Ther­a­peu­tics pen neu­ro­log­i­cal deal: Ipsen and Sky­hawk plan to de­vel­op small mol­e­cules that can mod­u­late RNA in a deal worth up to $1.8 bil­lion. The up­front pay­ment was not dis­closed. The deal fo­cus­es on two rare neu­ro­log­i­cal dis­ease tar­gets. Sky­hawk is re­spon­si­ble for ear­ly re­search, and Ipsen is re­spon­si­ble for all de­vel­op­ment af­ter can­di­date nom­i­na­tion. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.